KMID : 0369820130430020101
|
|
Jorunal of Korean Pharmaceutical Sciences 2013 Volume.43 No. 2 p.101 ~ p.106
|
|
Antitumor effect of a newly synthesized celecoxib derivative encapsulated in liposome
|
|
Kim Bee
Shin Dae-Hwan Kim Hee-Doo Kim Jin-Seok
|
|
Abstract
|
|
|
A new cyclooxygenase-2 inhibitor (code: PCX-3) was synthesized as a sodium salt form of celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and tested for its anticancer activity using human colon adenocarcinoma cells (HT-29) in vitro. Anti-proliferative effect of HT-29 cells by PCX-3 in DPPC/Chol liposomes was more effective than the free PCX-3 by 2-folds (IC30 = 125 ¥ìM vs. 227.5 ¥ìM). The same liposomal formulation of PCX-3 also showed a 2-fold increased effect than the free one both in DNA fragmentation and caspase activity of HT-29 cells at 19-743 ¥ìM and 37?371 ¥ìM ranges, respectively, suggesting apoptosis-based anti-proliferative effect. Down regulation of prostaglandin E2 level of HT-29 cells by the treatment of liposomal PCX-3 was more profound than its free form at 0.001?0.002 ¥ìM range. These data suggest that the liposomal formulation of this newly synthesized PCX-3 could be re-visited as a new anticancer or chemo-preventive agent in the future.
|
|
KEYWORD
|
|
Celecoxib, Liposomes, Caspase, Anticancer drugs, COX-2
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|